Allarity Therapeutics, Inc. - Common stock (ALLR)

 

   - Completed quarter with $26.9 million in cash and restricted cash

        

        

       

- Stenoparib clinical development continues in relapsed small cell lung cancer and, under FDA Fast Track designation, in advanced ovarian cancer- Allarity has received a Notice of Allowance for new intellectual property covering its stenoparib-specific DRP® companion diagnostic- Strong financial position maintained with approximately $29.8 million in cash and restricted cash as of March 31, 2026

        

        

TARPON SPRINGS, Fla., April 27, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor— today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for its patent application covering the Company’s DRP® companion diagnostic specific to stenoparib.

        

    

        

    

        

TARPON SPRINGS, Fla., December 31, 2025 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today issued the following letter to shareholders from the Company’s Chief Executive Officer.Dear Shareholders,

    

- Kaplan-Meier analyses show for the first time that median Overall Survival exceeds 25 months for Platinum Resistant and Refractory Ovarian Cancer Patients receiving stenoparib/2X-121 twice daily

        

Power Metallic Mines Inc. (TSX-V: PNPN; OTCQB: PNPNF; Frankfurt: IVV) today announced the appointment of Seamus O’Regan Jr., Canada’s former Minister of Energy & Natural Resources, to its Board of Directors.

    

    - Successfully initiated enrollment in advanced Phase 2 ovarian cancer trial